Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanistic Study of Anti-Platelet Therapy in Atherosclerosis
NCT07169513Not yet recruiting
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
- Start
- Oct 2025
- Primary completion
- Jul 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, single-blind trial of aspirin and clopidogrel in atherosclerosis and Peripheral Arterial Disease (PAD) (2 arms), sponsored by Guy's and St Thomas' NHS Foundation Trust. Primary endpoint: Monocyte-platelet aggregates at 14 weeks. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
aspirinclopidogrel
03
Conditions
atherosclerosisPeripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT07169513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07169513.